Skip to main content
Top
Published in: Current Atherosclerosis Reports 2/2012

01-04-2012 | Coronary Heart Disease (J Farmer, Section Editor)

The J-Point Phenomenon in Aggressive Therapy of Hypertension: New Insights

Authors: Gurusher S. Panjrath, Sameer Chaudhari, Franz H. Messerli

Published in: Current Atherosclerosis Reports | Issue 2/2012

Login to get access

Abstract

In the era of aggressive control of cardiovascular risk factors such as hypertension, the mantra of “lower is better” has taken a strong foothold. Although there is clear epidemiologic evidence that lower blood pressure improves specific organ-related outcomes, this rule does not apply to all patients and definitely not all target organs. The concept of J-curve or adverse outcomes at lower blood pressure has been proposed for more than three decades but has recently come under increasing scrutiny. Specifically, a relationship between adverse cardiovascular outcomes and low diastolic blood pressure has been observed in multiple clinical trials. In this article we review the advances in understanding of the J-curve phenomenon and include a discussion on specific populations that might be at higher risk due to the J-curve relationship.
Literature
1.
go back to reference Frank E. Deutsches Archiv Fur Klin. Vol 103; 1911. Frank E. Deutsches Archiv Fur Klin. Vol 103; 1911.
2.
go back to reference Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35.PubMedCrossRef Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35.PubMedCrossRef
3.
go back to reference Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827–38.PubMedCrossRef Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827–38.PubMedCrossRef
4.
go back to reference Lewington S. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.PubMedCrossRef Lewington S. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.PubMedCrossRef
5.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA: The Journal of the American Medical Association. 2003;289(19):2560–71.CrossRef Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA: The Journal of the American Medical Association. 2003;289(19):2560–71.CrossRef
6.
go back to reference Stewart IMG. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. The Lancet. 1979;313(8121):861–5.CrossRef Stewart IMG. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. The Lancet. 1979;313(8121):861–5.CrossRef
7.
go back to reference Cruickshank J, Thorp J, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;329(8533):581–4.CrossRef Cruickshank J, Thorp J, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;329(8533):581–4.CrossRef
8.
go back to reference Waller PC, Isles C, Lever AF, Murray GD, McInnes GT. Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? J Hum Hypertens. 1988;2(1):7–10.PubMed Waller PC, Isles C, Lever AF, Murray GD, McInnes GT. Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? J Hum Hypertens. 1988;2(1):7–10.PubMed
9.
go back to reference Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-Curve phenomenon and the treatment of hypertension. JAMA: The Journal of the American Medical Association. 1991;265(4):489–95.CrossRef Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-Curve phenomenon and the treatment of hypertension. JAMA: The Journal of the American Medical Association. 1991;265(4):489–95.CrossRef
10.
go back to reference Chrysant S. Current status of aggressive blood pressure control. World Journal of Cardiology. 2011;3(3):65–71.PubMedCrossRef Chrysant S. Current status of aggressive blood pressure control. World Journal of Cardiology. 2011;3(3):65–71.PubMedCrossRef
11.
go back to reference •• Messerli FH, Panjrath GS. The J-Curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009;54(20):1827–34. This article is a comprehensive review of literature supporting the J-curve relationship and DBP over the past decade and discussion on the underlying pathophysiology.PubMedCrossRef •• Messerli FH, Panjrath GS. The J-Curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009;54(20):1827–34. This article is a comprehensive review of literature supporting the J-curve relationship and DBP over the past decade and discussion on the underlying pathophysiology.PubMedCrossRef
12.
go back to reference Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–25. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–25.
13.
go back to reference Group JS. Principal results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res. 2008;31(12):2115–27.CrossRef Group JS. Principal results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res. 2008;31(12):2115–27.CrossRef
14.
go back to reference Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly. Hypertension. August 1, 2010 2010;56(2):196–202. Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly. Hypertension. August 1, 2010 2010;56(2):196–202.
15.
go back to reference Oates DJ, Berlowitz DR, Glickman ME, Silliman RA, Borzecki AM. Blood pressure and survival in the oldest old. J Am Geriatr Soc. 2007;55(3):383–8.PubMedCrossRef Oates DJ, Berlowitz DR, Glickman ME, Silliman RA, Borzecki AM. Blood pressure and survival in the oldest old. J Am Geriatr Soc. 2007;55(3):383–8.PubMedCrossRef
16.
go back to reference Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST Substudy. Am J Med. 2010;123(8):719–26.PubMedCrossRef Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST Substudy. Am J Med. 2010;123(8):719–26.PubMedCrossRef
17.
go back to reference Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.PubMedCrossRef Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.PubMedCrossRef
18.
go back to reference de Craen AJM, Gussekloo J, Teng YKO, Macfarlane PW, Westendorp RGJ. Prevalence of five common clinical abnormalities in very elderly people: population based cross sectional study. BMJ. 2003;327(7407):131–2.PubMedCrossRef de Craen AJM, Gussekloo J, Teng YKO, Macfarlane PW, Westendorp RGJ. Prevalence of five common clinical abnormalities in very elderly people: population based cross sectional study. BMJ. 2003;327(7407):131–2.PubMedCrossRef
19.
go back to reference Hall W. Representation of blacks, women, and the very elderly (aged = 80) in 28 major randomized clinical trials. Ethn Dis. 1999;9:333–339. Hall W. Representation of blacks, women, and the very elderly (aged = 80) in 28 major randomized clinical trials. Ethn Dis. 1999;9:333–339.
20.
go back to reference Denardo SJ, Messerli FH, Gaxiola E, et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol. 2010;106(4):498–503.PubMedCrossRef Denardo SJ, Messerli FH, Gaxiola E, et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol. 2010;106(4):498–503.PubMedCrossRef
21.
go back to reference Messerli FH, Bangalore S, Htyte N, Ather S. Authors' Reply. Am J Cardiol. 2009;107(3):491–2.CrossRef Messerli FH, Bangalore S, Htyte N, Ather S. Authors' Reply. Am J Cardiol. 2009;107(3):491–2.CrossRef
22.
go back to reference • Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP, for the PITTTI. What is the optimal blood pressure in patients after acute coronary syndromes? Circulation 2010;122(21):2142–2151. In this trial of patients with recent acute coronary syndrome, DBP was found to be a predictor of poor prognosis. The J-curve relationship was observed with both SBP and DBP. • Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP, for the PITTTI. What is the optimal blood pressure in patients after acute coronary syndromes? Circulation 2010;122(21):2142–2151. In this trial of patients with recent acute coronary syndrome, DBP was found to be a predictor of poor prognosis. The J-curve relationship was observed with both SBP and DBP.
23.
go back to reference Fagard RH, Staessen JA, Thijs L, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167(17):1884–91.PubMedCrossRef Fagard RH, Staessen JA, Thijs L, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167(17):1884–91.PubMedCrossRef
24.
go back to reference Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27(7):1360–9.PubMedCrossRef Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27(7):1360–9.PubMedCrossRef
25.
go back to reference •• Bangalore S, Messerli FH, Wun C-C, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. European Heart Journal, 2010. This is a recent study on patients in whom the traditional cardiovascular risk factors were well controlled and demonstrated a J-curve relationship with DBP. •• Bangalore S, Messerli FH, Wun C-C, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. European Heart Journal, 2010. This is a recent study on patients in whom the traditional cardiovascular risk factors were well controlled and demonstrated a J-curve relationship with DBP.
26.
go back to reference •• Group AS. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–828. This is the first large, randomized controlled trial in diabetic patients showing no additional benefit from aggressive blood pressure lowering. •• Group AS. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–828. This is the first large, randomized controlled trial in diabetic patients showing no additional benefit from aggressive blood pressure lowering.
27.
go back to reference •• Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA: The Journal of the American Medical Association 2010;304(1):61–68. This is a substudy of INVEST showing no additional benefit of tight control of SBP in patients with diabetes and/or CAD. •• Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA: The Journal of the American Medical Association 2010;304(1):61–68. This is a substudy of INVEST showing no additional benefit of tight control of SBP in patients with diabetes and/or CAD.
28.
go back to reference Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–97.PubMedCrossRef Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–97.PubMedCrossRef
29.
go back to reference Appel LJ, Wright JT, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363(10):918–29.PubMedCrossRef Appel LJ, Wright JT, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363(10):918–29.PubMedCrossRef
30.
go back to reference • Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clinical Journal of the American Society of Nephrology 2009;4(4):830–837. This trial showed a J-curve relationship between DBP and adverse outcomes in participants with CKD. • Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clinical Journal of the American Society of Nephrology 2009;4(4):830–837. This trial showed a J-curve relationship between DBP and adverse outcomes in participants with CKD.
31.
go back to reference Mandell BF. Hypertension: do not worry about the "J curve” treat the patient. Cleveland Clinic Journal of Medicine. 2011;78(2):74–4.PubMedCrossRef Mandell BF. Hypertension: do not worry about the "J curve” treat the patient. Cleveland Clinic Journal of Medicine. 2011;78(2):74–4.PubMedCrossRef
32.
go back to reference Bryan W. Hypertension and the "J-Curve". J Am Coll Cardiol. 2009;54(20):1835–6.CrossRef Bryan W. Hypertension and the "J-Curve". J Am Coll Cardiol. 2009;54(20):1835–6.CrossRef
Metadata
Title
The J-Point Phenomenon in Aggressive Therapy of Hypertension: New Insights
Authors
Gurusher S. Panjrath
Sameer Chaudhari
Franz H. Messerli
Publication date
01-04-2012
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 2/2012
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-012-0233-4

Other articles of this Issue 2/2012

Current Atherosclerosis Reports 2/2012 Go to the issue

Coronary Heart Disease (J Farmer, Section Editor)

Pleiotropic Effects of Statins: The Role of Eicosanoid Production

Coronary Heart Disease (J Farmer, Section Editor)

Effects of Ethanol Intake on Lipoproteins

Coronary Heart Disease (J Farmer, Section Editor)

Current Concepts of the Role of Oxidized LDL Receptors in Atherosclerosis

Coronary Heart Disease (J Farmer, Section Editor)

The Role of Statin Therapy for Primary Prevention: What is the Evidence?

Coronary Heart Disease (J Farmer, Section Editor)

Coronary Heart Disease in Young Adults

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.